YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
2008年5月5日 - 2:00PM
PRニュース・ワイアー (英語)
MISSISSAUGA, ON, May 5 /PRNewswire-FirstCall/ -- YM BioSciences
Inc. (AMEX: YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology
company that identifies, develops and commercializes differentiated
products for patients worldwide, today announced that posters
describing research conducted on its pain management product
AeroLEF(TM) will be presented at The 27th Annual Scientific Meeting
of the American Pain Society, which takes place May 8-10, 2008 in
Tampa, Florida. The first poster presentation, entitled "A
randomized controlled trial demonstrates the efficacy, safety and
tolerability of Aerosolized free and Liposome-Encapsulated Fentanyl
(AeroLEF(TM)) via pulmonary administration", is scheduled to be
presented on Thursday, May 8, 2008 (Abstract #8448, Poster Board
number 265). The second poster presentation, entitled "Comparative
phase I PK study of Aerosolized free and Liposome-Encapsulated
Fentanyl (AeroLEF(TM)) demonstrates rapid and extended plasma
fentanyl concentrations following inhalation", is scheduled to be
presented on Thursday, May 8, 2008 (Abstract # 8395, Poster Board
number 243). The third poster presentation, entitled "Aerosolized
Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary
administration allows patients with moderate to severe
post-surgical acute pain to self-titrate to effective analgesia",
is scheduled to be presented on Friday, May 9, 2008 (Abstract #
8435, Poster Board number 264). About YM BioSciences YM BioSciences
Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. The
Company has two late-stage products: nimotuzumab, a humanized
monoclonal antibody that targets the epidermal growth factor
receptor (EGFR) and is approved in several countries for treatment
of various types of head and neck cancer; and AeroLEF(TM), a
proprietary, inhaled-delivery composition of free and
liposome-encapsulated fentanyl in development for the treatment of
moderate to severe pain, including cancer pain. This press release
may contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the
assumptions made in preparing forward-looking statements include
but are not limited to the following: that nimotuzumab will
continue to demonstrate a competitive safety profile in ongoing and
future clinical trials; that AeroLEF(TM) will continue to generate
positive efficacy and safety data in future clinical trials; and
that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: YM BioSciences Inc.
CONTACT: Thomas Fechtner, the Trout Group LLC, Tel. (646) 378-2931,
Email: ; James Smith, the Equicom Group Inc., Tel. (416) 815-0700 x
229, Email: ; Nominated Adviser, Canaccord Adams Limited, Ryan
Gaffney, Tel. +44 (0)20 7050 6500
Copyright